REMARKS

With entry of this amendment, Claims 1-6, 8-14, and 16-34 are pending. Claims 1-3, 10-12, and 23 have been amended. Claims 7 and 15 have been canceled, and new Claims 26-34 added. No new matter has been added by these amendments.

CONCLUSION

No new matter has been added by these amendments. In light of the amendments, Applicants are of the opinion that the application is now in condition for allowance. Such action is respectfully requested. If the Examiner believes any informalities remain in the application which may be corrected by Examiner's Amendment, or there are any other issues which can be resolved by telephone interview, a telephone call to the undersigned attorney at (404) 745-2421 is respectfully solicited.

Respectfully submitted,

KILPATRICK STOCKTON, L.L.P.

By: Janina A. Malone
Reg. No. 47,768

KILPATRICK STOCKTON, LLP
1100 Peachtree St.
Suite 2800
Atlanta, GA 30309-4530
Phone: (404) 745-2421
Fax: (404) 541-3290
Atty Docket: 18631-0121 (45115-264494)

MARKED COPY OF AMENDMENTS

1. (Amended) A method for detecting the activity of a compound [compositions that effect inflammation], comprising,

a) adding to [cells] a first cell culture a composition comprising a compound [suspected of effecting] with an unknown effect on inflammation;

b) adding a stimulatory agent to the first cell culture and to a second cell culture;

c) measuring an amount of secreted determinant of inflammation selected from the group consisting of NFκ-B, IL1-β, IL-11, m-CSF, fibrinogen, TNF-α, adhesion molecules, selectins, CRP, V-CAM-1, MCP-1 or PAI-1; and

d) comparing the amount of the determinant from [c) with an] the first cell culture to the amount of determinant from [cells treated with the stimulating agent] the second cell culture.

2. (Amended) The method of Claim 1, wherein b) adding a stimulatory agent to the first cell culture precedes a) the adding of a composition [suspected of effecting] with an unknown effect on inflammation to [cells] the first cell culture.

3. (Amended) The method of Claim 1, wherein a) adding a composition comprising a compound [suspected of effecting] with an unknown effect on inflammation to the first cell culture [cells]; and b) adding a stimulatory agent to the first cell culture, occur simultaneously.

10. (Amended) A method for detecting compositions that effect glycated protein accumulation, comprising,

a) adding to a first cell culture [cells] a composition comprising a compound [suspected of effecting] with an unknown effect on glycated protein accumulation;

b) adding a glycated protein to the first cell culture and to a second cell culture;

c) measuring the amount of secreted determinant of [the] glycated protein accumulation selected from the group consisting of NFκ-B, IL1-β, IL-11, m-CSF, fibrinogen, TNF α, adhesion molecules, selectins, CRP, V-CAM-1, MCP-1 or PAI-1; and

d) comparing the amount of the determinant from the first cell culture [c)] with [an] the amount of the determinant from cells from the second cell culture [which have been treated with a glycated protein].

11. (Amended) The method of Claim 10, wherein b) adding a glycated protein to a first cell culture precedes a) the adding of a composition with unknown effects on [suspected of effecting] glycated protein production to cells.

12. (Amended) The method of Claim 10, wherein a) adding a [composition] compound with unknown effects on [suspected of effecting] glycated protein production and b) adding a glycated protein to a first cell culture occur simultaneously.

23. (Amended) A method of treating inflammation, comprising administering to a human or animal an effective amount of a composition comprising at least one compound capable of effecting glycated protein accumulation for the treatment of inflammation-induced diseases, wherein the effect on glycated protein accumulation is determined by:

a) adding to a first cell culture a composition comprising a compound with an unknown effect on glycated protein accumulation;

b) adding a stimulatory agent to the first cell culture and to a second cell culture;

c) measuring an amount of secreted determinant of inflammation selected from the group consisting of NFκ-B, IL1-β, IL-11, m-CSF, fibrinogen, TNF-α, adhesion molecules, selectins, CRP, V-CAM-1, MCP-1 or PAI-1; and

d) comparing the amount of the determinant from the first cell culture to the amount of determinant from the second cell culture.